Cho et al (Genbank Accession No. U42604, Feb. 2, 1996).* |
Ritter et al (Genbank Accession No. M84127, Mar. 1996).* |
Ritter et al (Genbank Accession No. M84128, Jan. 1995).* |
Ritter et al (Genbank Accession No. M84126, Jan. 1995).* |
Genbank Attachment #1: sequence search results.* |
Genbank Attachment #2: pertinant sequences.* |
Koiwai et al. “Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase”. Hum. Mol. Genetics, vol. 4, No. 7, pp. 1183-1186, Jul. 1995.* |
Ritter et al “Cloning of two human liver bilirubin UDP-glucuronolsyltransferase cDNAs with expression inCOS-1 cells.” J. of Bio. Chem. vol. 266, No. 2, pp. 1043-4017, Jan. 1991.* |
Aono et al. “Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome” The Lancet, vol. 345, pp. 958-959, Apr. 15, 1995.* |
Cronin et al. “Cystic Fibrosis mutation detection by hybridization to light-generated DNA probe arrays” Human Mutation, Vil 7, pp. 244, 255, 1996.* |
Strassburg et al “Differential expression of the UGT1A locus in human liver, Biliary, and gastric tissue” Molecular Pharmacology, vol. 52, pp. 212-220, 1997.* |
Ciotti et al “Genetic polymorphism in the human UGT1A UDP-Glucuronosyltransferase” Am J. of Human Genetics, vol. 61, No. 4, pp. 1149, OCt. 1997.* |
Yamamoto et al. “Analysis of bilirubin uridine 5′-diphosphate (UDP-glucuronosyltransferase gene mutations in seven patients with Crigler-Najjar syndrome type II” J. Hum. Genet, vol. 43, pp. 111-114, 1998.* |
Flores-Diaz et al. “Cellular UDP-glucose Deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene” J. of Biological Chemistry, vol. 272, No. 38, pp. 23784-23791, Sep. 1997.* |
Koiwai et al. “Crigler-Najjar syndrome type II is inherited both as a dominant and as a recessive trait”Human Molecular Genetic, vol. 5, No. 5, pp. 645-647, 1996.* |
Aono et al. “A new type of defect in the gene for bilirubin uridine 5′diphosphate-glucuronosyltransferase in a patient with crigler-Najjar syndrom Type I” Pediatric Research, vol. 35, No. 6, pp. 629-632, 1994.* |
Labrune et al “Genetic heterogeneitiy of Crigler-Najjar syndrom type I: a study of 14 cases” Human Genetics, vol. 94, pp. 693-697, 1994.* |
Daly et al. “Metabolic polymorphisms” Pharmac. Ther. vol. 57, pp. 129-160, 1993.* |
GenBank Alignment Packet #2.* |
GenBank Accession No. M84122. |
GenBank Accession No. M84123. |
GenBank Accession No. M84124. |
NCBI Entrez Accession No. M84125. |
NCBI Entrez Accession No. M84127. |
NCBI Entrez Accession No. M84128. |
NCBI Entrez Accession No. M84129. |
NCBI Entrez Accession No. M84130. |
NCBI Entrez Accession No. U39550. |
NCBI Entrez Accession No. U42604. |
OMIM Entry 191740. |
OMIM Entry 218800. |
NCBI Entrez Accession No. M84130. |
Bosma et al., New Eng. J. Med., 333(18):1171-1175 (1995). |
Burchell et al., Life Sciences, 57(20):1819-1831 (1995). |
Ciotti et al., Pharmacogenetics, 7:485-495 (1997). |
Iwano et al., Biochem. J., 325:587-591 (1997). |
Mackenzie et al., Pharmacogenetics, 7:255-269 (1997). |
Miners et al., Pharmac. Ther., 51:347-369 (1991). |
Monaghan et al., Lancet, 347:578-581 (1996). |
Owens et al., Pharmacogenetics, 2:93-108 (1992). |
Ritter et al., J. Biological Chem., 267(5):3257-3261 (1992). |